Compensatory PI3K pathway activation might be a serious problem in the clinical setting, where BRAF- and MEK inhibitors can encounter intrinsic [50-52] as well as acquired [5, 9] PI3K pathway reactivation which is likely involved in tumor relapse. Here, MAP2K7 is linked to neoplasm.